Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
HERNEXEOS (ZONGERTINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
HERNEXEOS
NDA
Get alerts
ZONGERTINIB | N219042 | BOEHRINGER INGELHEIM PHARMACEUTICALS INC
1 strength
2 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
2 unique patents, 1 exclusivity by expiration date
Expiring < 1yr (1)
Active (1)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
11608343
Jul. 21, 2041
12171739
Nov. 15, 2026
NCE
Aug. 8, 2030
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 60MG
RLD
2 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Aug 8, 2025
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
11608343
Jul 21, 2041
—
Yes
Yes
U-4245
USE OF ZONGERTINIB FOR TREATING NON-SMALL CELL LUNG CANCER (NSCLC)
—
12171739
Nov 15, 2026
—
Yes
Yes
—
—
Exclusivities (1)
Code
Date
Status
NCE
Aug 8, 2030
Active